MAP1LC3B and prostate carcinoma: Three SNPs, ATG16L1 rs78835907, ATG16L1 rs13021297, and MAP1LC3B rs8044820, remained significant (Table 2 and Fig. 1A), and were selected to replicate findings in advanced prostate cancer cohort.